Graybill Wealth Management LTD. Boosts Holdings in Becton, Dickinson and Company (NYSE:BDX)

Graybill Wealth Management LTD. grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,530 shares of the medical instruments supplier’s stock after acquiring an additional 139 shares during the quarter. Graybill Wealth Management LTD.’s holdings in Becton, Dickinson and Company were worth $4,227,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth $26,000. Sound Income Strategies LLC raised its stake in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Opal Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at $45,000. Abound Wealth Management boosted its position in Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares during the period. Finally, Chilton Capital Management LLC boosted its position in Becton, Dickinson and Company by 1,233.3% during the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 185 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded down $0.90 during trading hours on Tuesday, hitting $239.62. The company had a trading volume of 123,122 shares, compared to its average volume of 1,384,083. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The firm has a market cap of $69.25 billion, a P/E ratio of 52.96, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $262.23. The business has a fifty day simple moving average of $237.14 and a 200-day simple moving average of $235.16.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same period last year, the firm posted $2.96 EPS. Becton, Dickinson and Company’s quarterly revenue was up 2.3% compared to the same quarter last year. Equities analysts predict that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Analyst Ratings Changes

BDX has been the topic of a number of recent research reports. Raymond James reduced their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus upped their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.